Close

Edwards Lifesciences (EW) Reports In-Line Q3 EPS

October 25, 2016 4:17 PM EDT

Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.68, in-line with the analyst estimate of $0.68. Revenue for the quarter came in at $739.4 million versus the consensus estimate of $749.14 million.

GUIDANCE:

Edwards Lifesciences sees Q4 2016 EPS of $0.67-$0.77, versus the consensus of $0.74. Edwards Lifesciences sees Q4 2016 revenue of $750-790 million, versus the consensus of $801.14 million.

Edwards Lifesciences sees FY2016 EPS of $2.82-$2.92, versus the consensus of $2.88. Edwards Lifesciences sees FY2016 revenue of $2.7-3.0 billion, versus the consensus of $2.94 billion.

"We are pleased to report strong third quarter underlying sales growth of 18 percent, which was consistent with our increased expectations," said Michael A. Mussallem, chairman and CEO. "2016 has been a remarkable year for our company. This performance reflects continued strong global adoption of our Edwards SAPIEN 3 valve platform, which remains on track to generate over $300 million more in sales than we originally expected for the year. Consistent with our strategy, we are aggressively investing to bring break-through therapies to an even broader group of patients around the world."

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Management Comments

Related Entities

Earnings